FDA Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) recenlty granted Fast Track Designation for MuSK-CAART, or muscle-specific kinase (MuSK) chimeric autoantibody …
FDA Grants Cabaletta Bio Fast Track Designation for MuSK-CAART Read More